CD BioGlyco provides progressive Technologies for HMO Production for our clients. We have cutting-edge technology platforms which offers one-stop services to meet clients’ needs in the field of glycoscience.
The first-rank food for newborn babies is human milk which has been confirmed to possess a large number of effects of promoting growth and providing defense against illnesses. HMOs are the third most plentiful constituent of milk, after lipids and Lactose, with total mean concentrations ranging from 4-30 g/L. The majority of these complicated carbohydrates are typically based on free lactose. While they are indigestible by infants, HMOs provide many benefits to it, such as Antimicrobial action, prevention of viral pathogens, promotion of healthy gut microbiota, and growth of the immune and nervous systems. HMOs may also act a part in preventing allergic reactions in children.
There are three crucial HMO types in breast milk. Sialylated HMOs account for 12%-14%, non-fucosylated neutral HMOs account for 42%-55%, and fucosylated HMOs account for 35%-50%. LNnO is a crucial neutral HMO. The core structure of LNnO is shown in Fig.1.
Fig.1 The core structure of LNnO. (CD BioGlyco)
There have been many types of research on the synthesis of HMOs industrially, for use as probiotics. Many approaches at CD BioGlyco have been used, including direct chemical syntheses, the use of recombinant glycosyltransferase (GT) activities; transglucosidase reactions, in which glycohydrolases act in reverse to attach monosaccharides to oligosaccharides; and through reconstruction of Leloir-type pathways to synthesize the preferred HMO substrate of bifidobacteria, lacto-N-biose I. LNnO can be synthesized via chemical synthesis which uses the dimethylmaleoyl moiety as an amino protective group at CD BioGlyco. We also use living E. coli JM109 cells (lacY+ lacZ-) that overexpress Neisseria meningitides β1-3-N-acetylglucosaminyltransferase (NmLgtA) and Neisseria meningitides β1-4GalT (NmLgtB) to produce LNnO.
In order to ensure product quality, CD BioGlyco provides HMO analysis service. We use chromatography and mass spectrometry which is the most common approach for the analysis of LNnO.
CD BioGlyco has much scientific research to offer solutions to produce diversified carbohydrates. We will customize special programs according to clients' needs. We have a high performance-to-price ratio to provide one-station production services. If you are interested in our services, please feel free to contact us for more detailed information.
Reference
